We saw a non-significant trend toward increased numbers of tumor-infiltrating CD4+ and CD8+ T cells in PeptiBAC-Trp2-treated tumors compared with BCG, anti-PD-1 alone and BCG in combination with anti-PD-1 ICI-treated tumors. Here, CD8A is linked to neoplasm.